Рыночные новости
Заголовки по акциям и крипте из Alpaca. Храним 7 дней. Всего: 9492.
-
TME Pharma Publishes Semi-Annual Results and Half-Year ReportTME Pharma N.V. released its financial results for the first half of 2026, reporting a net loss of €0.51 million and a cash position of €1.02 million as of June 30, 2026.
-
Dantax A/S - Managers' TransactionsDantax A/S has announced a change in shareholdings for individuals with management responsibilities in accordance with the EU Market Abuse Regulation.
-
SenzaGen Announces Q3 2026 Earnings Report Date and WebcastSenzaGen AB has scheduled the release of its third-quarter 2026 financial report for November 5, 2026, to be followed by a live presentation.
-
Audacia Announces Availability of 2026 Semi-Annual Financial ReportAudacia SA has made its semi-annual financial report for the period ending June 30, 2026, available to the public and filed it with the Autorité des marchés financiers.
-
Proactis S.A. Postpones Publication of Half-Yearly ResultsProactis S.A. has announced the postponement of its half-yearly results for the period ending July 31, 2026, due to delays in finalizing the annual accounts for the previous fiscal year.
-
Drillcon AB Reports Q3 2026 Financial ResultsDrillcon AB announced a 14.9% year-over-year increase in Q3 revenue and an improvement in EBIT margin to 6.8%.
-
Elicera Therapeutics Co-Founder Awarded SEK 4 Million Grant for CAR-T ResearchElicera Therapeutics announced that co-founder Dr. Di Yu has received a four-year research grant from the Swedish Research Council to study CAR-T cell design for solid tumors.
-
Starbreeze AB Announces Monthly Share ConversionStarbreeze AB reported the conversion of 7,080 series A-shares into series B-shares, resulting in a change to the company's total number of votes.
-
Climeon Announces Nomination Committee for 2027 Annual General MeetingClimeon AB (publ) has announced the composition of its Nomination Committee in preparation for the 2027 Annual General Meeting.
-
Obiz SA Reports Record FY25/26 Revenue and Reaffirms EBITDA TargetObiz SA announced record revenue of €144.9 million for the FY25/26 period and reaffirmed its €7 million EBITDA target for FY26/27.
-
Minesto Releases Recording of Q3 Update WebinarMinesto AB has made the recording of its Q3 update webinar, featuring CEO Dr. Martin Edlund and CFO Alexander Jancke, available to the public.
-
Lhyfe Expands Logistics Fleet for Green Hydrogen DeliveriesLhyfe has increased its bulk green hydrogen logistics capacity by adding 10 new Hexagon Purus containers to its European fleet.
-
Huddlestock Fintech AS Appoints Ramtin Matin as Interim CEOHuddlestock Fintech AS has replaced CEO Leif Arnold Thomas with Ramtin Matin, who will serve as interim CEO effective immediately.
-
Forsee Power Announces 2026 Half-Year ResultsForsee Power reported its financial results for the first half of 2026, highlighting a challenging market environment and a strategic transformation aimed at a 2027 rebound.
-
KDventures Writes Down Umecrine Cognition Stake to SEK 0 Following Trial FailureKDventures AB has written down the value of its holding in portfolio company Umecrine Cognition to zero after the drug candidate golexanolone failed to meet efficacy endpoints in a clinical trial.
-
pferdewetten.de AG Reports Major Voting Rights Notificationpferdewetten.de AG announced a change in major voting rights, with Robus Capital Management Limited reporting a total position of 20.11%.
-
Catena Media plc Announces Share Buybacks Executed from 26 to 30 October 2026Catena Media plc reported the repurchase of 235,599 of its own ordinary shares between October 26 and October 30, 2026, as part of its ongoing buyback program.
-
Q-linea Reports Q3 2026 Financial Results and Operational ProgressQ-linea announced its third-quarter 2026 financial results, highlighting increased sales, narrowed EBIT losses, and expanded ASTar placements.
-
FCR Immobilien AG Reports Director Dealings by MAMBO Vermögensverwaltung GmbHFCR Immobilien AG announced that MAMBO Vermögensverwaltung GmbH, an entity closely related to board member Falk Raudies, purchased company shares in an off-market transaction.
-
Xbrane Biopharma Releases Interim Report for January-September 2026Xbrane Biopharma AB published its interim report for the first nine months of 2026, detailing financial performance and operational updates.